lotus
PHARMACEUTICAL

Lotus Pharmaceutical

Supplier Conference

24 June 2026

SUPPLIER CONFERENCE AGENDA



S. No.	Topic	Speaker	Taiwan Time
1	Opening of Conference	Ella	14:00 pm
2	R&D - Presentation	Vivek	14:10 pm
3	Strengthening Cybersecurity Across the Supply Chain Ecosystem	Gwen	14:30 pm
4	Lotus ESG	Susan	14:50 pm
5	Regulatory Presentation	Adam	15:10 pm
6	Supply Chain Management - Website Walk through	Amy	15:30 pm
7	Open PO expediting Process	Betty Chiu	15:45 pm
8	Code of Conduct	Keerthi Reddy	16:00 pm
9	Supplier Evaluation & Best Service Supplier 2025	Amit Razdan	16:15 pm



Opening

Ella

Major Milestones Defining Lotus Pharmaceutical's Journey

1966 — **Founded in Taiwan**

2014 — **Lotus and Alvogen merge Asian operations**

2019 — Lotus launched its **first P4 product** Buprenorphine/ naloxone in the US through Alvogen US

2020 — **Qsymia®** launch in Korea

2021 — **Petroleum Authority of Thailand (PTT) invested in Lotus**, strategic partnership in southeast Asia

2022 — Lotus launched **lenalidomide** in the US

Acquisition of **Alimta®** and **Cialis®** from Eli Lilly for Taiwan

2024 — **Acquisition of Teva pharma Thailand**

Acquisition of **Alpha Choay ®** from Sanofi for Vietnam

2025 — Completion of the acquisition of 100% share of **Alvogen US**



Lotus is Well Positioned for Sustainable Growth

$2.5bn*
Market Cap

- Largest pharma company listed on Taiwan Stock Exchange
- $656m revenue in 2025 with 20%+ CAGR since 2014

*As at 2 March 2026

300+
COMMERCIAL PRODUCTS

- Marketed in 90+ countries
- B2C in Asia and the US
- B2B for export to rest of the World

100+
R&D+ BD PIPELINE

- Brand new R&D center in Hyderabad
- 60+ R&D pipeline of complex Gx and 505b2
- 70+ BD pipeline including NCE, biosimilars, 505b2 and Gx in oncology, CV, CNS, etc.

4
MANUFACTURING SITES

- USD70m Capex investment in 2020-2024
- TW facility – GMP certifications from US FDA, EMA, PMDA and ANVISA
- US facility – GMP certifications with Exemplary FDA quality record

100+
GLOBAL PARTNERSHIPS

- MNCs – Eli Lilly, Novartis, Takeda, Astra Zeneca
- Global and regional leading pharma companies –Vivus, Sandoz, Stada, Zentiva, SteinCares, Delpharm etc.

2,200+
EMPLOYEES

- 600+ S&M
- 900+ Operation & Quality
- 200+ R&D
- 60+ RA

R&D-Presentations

Mr. Vivek Dubey

TODAY'S CONVERSATION

Agenda

01 **Lotus- Evolution and Meishi R&D**

Lotus R&D overview

02 **Drug Substance — Two Vendor Scenarios**

Ready-DMF vs. Co-Development pathways

03 **Reference Standards & Logistics**

FOC supply for impurities, working & reference standards

04 **Excipients & Coating Systems**

Pharmacopoeial compliance and method equivalency

05 **Deficiencies & Change Notifications**

Communication protocol and ad-hoc support


06 **The Path Forward**

Vendor excellence benchmark and partnership commitment

Lotus– R&D Capabilities







Lotus RD site (Hyderabad, India)

- **Meishi Pharma India (Lotus' R&D) facility is spread over ≅ 20K sq feet in a 15-acre campus housing RDs from leading Global companies**
  - Lab area ≅ 14K sq ft; Office Area ≅ 6K sq ft
  - Can accommodate about 70-90 people
  - Office/administrative area opened for use
  - State of the art facility for development of solid oral oncology/non-oncology

- The R&D team covers professional fields such as formulation and analytical development, project management, intellectual property, clinical research, R&D quality, and packaging, supported by in-house clinical research centers.

- Lotus's products are manufactured in our own factories certified by the U.S. FDA, Taiwan TFDA, Japan PMDA, and EU EMA, or in approved partner manufacturing facilities.



Hyderabad, Telangana



Genome Valley



Neovantage Research park

DRUG SUBSTANCE

Two vendor scenarios — one quality bar

SCENARIO 1

Ready DMF at Kick-Off

- Complete analytical package to be available on Day 1
- DMF in place: US and Europe
- Validated methods, stability, hygroscopicity, pXRD, PSD, microbial — all delivered upfront
- All risk assessments (Genotox, Residual Solvents, Nitrosamines) submitted with kick-off
- Patent/IP compliance with polymorph confirmation data

SCENARIO 2

Vendor in Co-Development

- Phased delivery model with defined quality gates
- Phase 1(kick-off) — basic methods, dev reports, R&D batch stability
- Phase 2 (pilot bio-batch) — full analytical package, method validation, all risk assessments
- **Open part of DMF must be closed before CB batches**

SCENARIO 1 · READY DMF

Analytical data package required at kick-off

Analytical Technical Package

Complete dossier including method validation as per the CoA

Forced Degradation Report

Acid / base / oxidative / thermal / photolytic per ICH Q1A(R2) and Q1B

API Stability Data

Long-term 25 °C/60% RH and accelerated 40 °C/75% RH — ICH Q1A(R2)

Hygroscopicity Report

DVS-based moisture sorption profile with classification

Recommended Storage Conditions

Justified by stability and hygroscopicity data

pH-Solubility Profile

Across physiological range pH 1.2 – 6.8 for each polymorphic form

pXRD Method & Stability

Validated; capable of detecting alternate forms with LOD/LOQ; Form stability data (compaction, milling, moisture and thermal exposure etc.)

PSD Method Validation

Aligned to proposed specification (laser diffraction or equivalent)

Microbial Spec & Validation

USP <61>/<62> and Ph. Eur. 2.6.12/2.6.13 — TAMC, TYMC, specified organisms

SCENARIO 1 · READY DMF

Risk assessment reports — non-negotiable at kick-off

GENOTOXIC IMPURITIES

ICH M7(R2)

- Class 1–5 classification with rationale
- (Q)SAR assessment (DEREK + Sarah, or equivalent dual platforms)
- Control strategy: purge factor analysis or specification limit
- PDE / TTC justification document

RESIDUAL SOLVENTS

ICH Q3C(R8) · USP <467> · Ph. Eur. 5.4

- Class 1, 2 and 3 solvent declaration per process step
- PDE basis for any Class 2 above option-1 limit
- Unlisted solvents — class-by-read-across with full justification
- Validated GC method or vendor cross-reference

NITROSAMINES

FDA Guidance · EMA Art. 5(3) Referral

- Risk assessment for general nitrosamines and listed NDSRIs
- Root-cause evaluation: amines + nitrosating sources across route
- Control / mitigation strategy (in-process, fate & purge)
- AI-based limits — confirmatory testing where indicated

All three reports must be signed, current-version, and traceable to current FDA / EMA expectations.

SCENARIO 1 · IP COMPLIANCE

Polymorph form — patent-clear and analytically defensible

OUR EXPECTATION

Patent-clear polymorphic form

Novel Polymorph supplied must not infringe innovator or third-party patent claims in the target jurisdictions (US & EU).

Form selection rationale documented with literature and patent landscape review.

REQUIRED SUPPORTING DATA

Form-identifying analytical evidence

pXRD	Full pattern with peak table; reference comparison to claimed forms
DSC	Thermogram with onset, peak, ΔH for each thermal event
FT-IR / Raman	Where the form is claimed by vibrational fingerprint
TGA	Mass loss profile, hydrate / solvate identification
ssNMR	Where polymorph differentiation requires it (ICH Q6A decision tree)

SCENARIO 2 · CO-DEVELOPMENT

Phase 1 — Initial deliverables at project initiation

Kick-off (Phase 1) → Pilot Bio-Batch (Phase 2) → DMF Closure → CB Batches → Filing

Deliverables at project kick-off

Basic analytical methods

Assay, related substances,, water content, residual solvents

Method development reports

With rationale, selectivity demonstration, preliminary system suitability

Forced degradation data

Initial stress-condition screening; preliminary degradant profile

Hygroscopicity data

Sorption behaviour to guide storage and handling

pH-dependent solubility data

Profile across physiological pH range

pXRD method

For form identification at R&D batches

PSD method

Wet/dry dispersion strategy locked early

Stability data — R&D batches

Initial timepoints in target packaging configuration

SCENARIO 2 · CO-DEVELOPMENT

Phase 2 — The pilot bio-batch quality gate



01

Complete analytical technical package

All methods finalized, transferred, and ready for validation

02

Method validation and Spec/STP aligned to CoA

Specificity, accuracy, precision, linearity, range, LOD/LOQ, robustness — per ICH Q2(R2)

03

All risk assessment reports

Genotoxic impurities (ICH M7) · Residual solvents (ICH Q3C) · Nitrosamines (FDA / EMA)

SCENARIO 2 · REGULATORY GATE

Open DMF — closure required before confirmatory (CB) batches



oDMF must be available before CB batches. All risk assessment reports mandatory at this stage

Reference standards & impurities — FOC supply at kick-off

At project initiation, vendors are expected to supply the following materials free of cost (FOC):

Each Impurity

25 mg

Per identified impurity (specified, unspecified, degradants)

Working Standard

5 g

Qualified against the primary / reference standard

Reference Standard

1 g

Fully characterized; CoA + full identity package

NDSRI Standard

10 mg

Per nitrosamine drug-substance-related impurity flagged in the risk assessment

Ongoing supply — Development & Validation

Continued replenishment of impurities, working standards, reference standards and NDSRIs through PO-based activities during both development and validation phases.

EXCIPIENTS

Core documentation — pharmacopoeial compliance



Certificate of Analysis

Lot-specific CoA covering every monograph / specification parameter, with method reference and acceptance criteria.



Specifications

Documented specification aligned to USP-NF (US), Ph. Eur. (EU), JP and any other target market — current edition.



Complete Test Methods

Full test methods provided as per market compliance requirements: US, EU, JP and others as applicable.

US — USP-NF · **EU** — Ph. Eur. · **JP** — JP · **Others** — as per target dossier

When in-house methods replace pharmacopoeial methods

Vendor uses an in-house method

instead of the USP / Ph. Eur. / JP monograph method

Then both of the following are required →

1

Complete method validation report

Per ICH Q2(R2): specificity, linearity, accuracy, precision (repeatability & intermediate), range, LOD/LOQ, robustness, system suitability.

2

Method equivalency report

Side-by-side comparison vs. monograph method on common sample sets, with statistical evaluation (t-test / F-test or equivalent) demonstrating equivalence.

Why we insist

Both US and EU reviewers expect either a compendial method or a fully justified scientifically equivalent alternative. Without the equivalency report, deficiencies are inevitable.

Opadry & Assessment report/Declarations — what we need

Opadry color standards

Vendors shall supply respective color reference standards for:

- R&D release · formulation development batches and visual comparator
- Plant release · exhibit and validation batch QC release at the manufacturing site

Signed assessment reports

All material assessment reports provided in signed copy — TSE/BSE, allergens, GMO, residual solvents, elemental impurities (ICH Q3D), microbial, residual solvents assessment and Nitrosamine assessments, E&L as per USP <665> wherever applicable

Signed declarations

Compendial compliance, food-grade where applicable, IPEC GMP statement, country-of-origin.

COMMUNICATION · CHANGE CONTROL

Deficiencies & change notifications — three pillars



AGENCY DEFICIENCY LETTERS

- Proactively inform us when a DL is received at the vendor end.
- Share the full submitted response with us promptly.
- Flag overlapping issues that may impact our submission.



SPEC / METHOD CHANGES

- Communicate every change in specifications or test methods through formal notification.
- Notify before implementation, not after.
- Include change rationale and impact assessment.



FINISHED-PRODUCT DL SUPPORT

- Provide ad-hoc supply of impurities, reference and working standards during our FP deficiencies.
- Make subject-matter experts available for technical Q&A.
- Support root-cause and CAPA documentation as needed.

Common Packaging Materials requirement at Lotus Pharma



Requirements from Packaging Vendors

- ❑ DRUG MASTER FILE (DMF), US FDA & HEALTH CANADA
- ❑ DRUG MASTER FILE (DMF), China
- ❑ Specimen COA
- ❑ Technical Data Sheet
- ❑ Storage Conditions
- ❑ Shelf Life/retest period
- ❑ IR spectrum
- ❑ Supplier name and mfg. address Declaration Letter
- ❑ USP Compliance Certificate 661.1, 661.2, USP 670, USP 671
- ❑ US FDA FOOD CONTACT STATUS (21 CFR)
- ❑ EU FOOD CONTACT STATUS (EU No. 10/2011)
- ❑ ICH Q3C, Q3D statement- (Elemental impurity)
- ❑ Nitrosamines/Nitrocellulose Declaration statement
- ❑ ISO Statement
- ❑ BSE/TSE Certificate
- ❑ Material Safety Data Sheet
- ❑ Compliance with ISO 8317 (Child-resistance) – For Bottles with CR closure only.
- ❑ Drawings: For Bottles/ Closures/ Desiccants
- ❑ MOQ
- ❑ Delivery Lead Time

THE PATH FORWARD

What “good” looks like — our vendor excellence benchmark

- Day-1 package: validated methods, stability, hygroscopicity, pXRD, PSD, microbial, solubility.
- All three risk assessments — Genotox, Residual Solvents, Nitrosamines — signed and current.
- Patent-clear polymorph confirmed by pXRD, DSC, and supporting techniques.
- DMF (US Type II / EU CEP or ASMF) closed and aligned before CB batches.
- FOC supply of impurities (25 mg), working std (5 g), reference std (1 g), NDSRI (10 mg) at kick-off.
- Excipients: CoA + specs + complete methods per USP / Ph. Eur. / JP — or validated, equivalent in-house alternatives.
- Opadry color references for both R&D and plant release, with signed declarations.
- Proactive communication on DLs and formal pre-change notifications — no surprises.

Hit all eight, every time — and we file faster, together.

Strengthening Cybersecurity Across the Supply Chain Ecosystem

Gwen

AI Security

Governance, Verification & Ecosystem Protection

A Secured Data Platform

- Enterprise-grade (or commercial version) AI environments only
- No training on company data — zero-retention policy enforced
- AI compliant platforms (e.g. Claude, Azure OpenAI)

B Double-Check Before Sharing

- All AI-generated outputs reviewed by responsible team before release
- Hallucination risk flagged — mandatory human-in-the-loop sign-off
- Sensitive buyer/supplier data redacted prior to AI processing

C AI Governance Supplier Ecosystem

- AI usage policies cascaded to key suppliers & partners
- Supplier onboarding includes AI data-handling clauses
- Quarterly AI compliance audit

lotus PHARMACEUTICAL

AI-Based Supplier Scoring

Intelligent Performance Monitoring for Supplier Ecosystem

94.2% ▲ +2.1%

On-Time Delivery Score

AI tracks shipment milestones in real time and scores each supplier against committed lead times, flagging delays before they impact production.

3.8% ▼ -0.5%

Quality Issues Rate

AI aggregates defect reports, inspection failures & returns. Low scores auto-trigger corrective action requests (CARs) with root-cause prompts.

88.5% ▲ +4.3%

SLA & Compliance Breaches

AI monitors contract SLAs, delivery terms and regulatory obligations. Non-compliance events are auto-scored and escalated to procurement.

Supplier Performance Dashboard

Supplier	Delivery	Quality	SLA	Score	
Supplier A	96%	98%	95%	96	Gold
Supplier B	88%	91%	84%	88	Silver
Supplier C	73%	80%	70%	74	Bronze
Supplier D	61%	68%	55%	61	Review
Supplier E	90%	94%	88%	91	Gold

How AI Scores Suppliers

- Applies weighted scoring model: Delivery 40% · Quality 35% · SLA/Compliance 25%.
- Auto-generates alerts for Score < 75 and escalates to category manager with recommended action.

lotus PHARMACEUTICAL

Supplier Cybersecurity

Partnership in Protecting Our Shared Digital Ecosystem – Shared Responsibility

60%
of data breaches originate from the supply chain

287
average days to detect & contain a supply chain breach

$4.5M
average cost of a supplier-linked cyber incident

Data Encryption
All data in transit and at rest must be encrypted

Access Control
Role-based access with MFA enforced for all Lotus-connected systems

Vulnerability Mgmt
Monthly patch cycle; critical CVEs remediated within 72 hours

Incident Reporting
Notify Lotus within 24 hrs of any breach or suspected compromise

Area	Lotus Responsibility	Supplier Responsibility
Network Security	Perimeter firewall, SIEM monitoring	Segment Lotus-facing systems, no lateral access
Identity & Access	SSO provisioning, access reviews	MFA on all accounts, quarterly access audits
Software / Patches	Lotus platform patching	Keep all integrated software current & scanned
Data Handling	Data classification & DLP policies	No unauthorised storage of Lotus data externally
Incident Response	IR coordination & forensics support	24-hr notification + containment actions
Third-Party Risk	Vendor risk scoring & onboarding review	Apply same standards to your own sub-suppliers

lotus PHARMACEUTICAL

Building a Resilient, Agile and Proactive Risk Management Supply Chain

Ensure uninterrupted access to high-quality medicines through robust supplier partnerships

Key Pillars

Top Disruption Drivers	Mitigation Strategies	Focus on Delivering Value
Data Insight: 72% of pharma firms experienced supply delays in the past 12 months	Dual/multi-sourcing critical inputs	Supplier partnership model, Joint KPIs, CI and business reviews
Geopolitical instability	Strategic sourcing diversification, including KSMs	Real-time risk monitoring platforms and Audit readiness
Raw material shortages	Supplier Collaboration and Innovation	Transparent documentation. Minimize changes and timely change notifications
Regulatory shifts such as stricter GMP enforcement (e.g., US FDA, EMA, NMPA) and Increased scrutiny on traceability and data integrity	Inventory buffers and Rapid response to changes (intrinsic and extrinsic)	Embedding ESG into the Supply Chain Core - Carbon footprint reduction and Waste management
	Balanced Score-card approach i.e. Quality Vs. Cost Vs. Service Reviews	Ethical practices and pricing
	Compliance as a Competitive Advantage	

lotus
PHARMACEUTICAL

Lotus ESG

Susan Liao

lotus
PHARMACEUTICAL

Health is a right, not a privilege.



Patient needs are at the heart of everything we do.

Through a diverse portfolio, global partnerships, and worldwide reach, we expand access to medicines while addressing unmet medical needs.

Lotus Confidence in Every Dose, From Taiwan's #1 to the Global Top 20



Top 20

Global Specialty Pharma

- Acquired Alvogen US, propelling Lotus into the Global Top 20 Specialty Pharma.

No. 1

Taiwan’s #1 Listed Pharma Company by Revenue

- NT$ 20.5 Billion in 2025 Revenue
- 7 Consecutive Years of double-digit revenue growth.


4 Years

Consecutive HR Asia Awards

- Best Companies to Work for in Asia (Taiwan) - four years in a row
- Diversity, Equity & Inclusion Awards - 2nd time winner

lotus PHARMACEUTICAL

Achieving Double-Digit Revenue Growth While Driving Environmental Responsibility



2025 Revenue NT$20.5 Billion

7th consecutive year of double-digit growth



28% GHG Emissions Reduction

GHG emissions at major operating sites (Taiwan & Korea) vs. 2022 baseline



BD & Licensing

Signed 48 business development licensing and 19 out-licensing partnerships



214 New SKUs Launched

114 global submissions, and launched 214 products



Low-Carbon Equipment

Replaced oil boilers with gas boilers to reduce emissions



Green Logistics

Switched to eco-friendly cold chain packaging

lotus PHARMACEUTICAL

Enhancing Local Sourcing to Build a Sustainable Supply Chain

53% → **63%**

2024 — 2025

Increasing Local Sourcing Ratio

Local Sourcing Impact

Lower Transportation Emissions

Reduced logistics distance through localized sourcing

Supporting Local Economies

Strengthened partnerships with local suppliers and Communities

Reducing Supply Chain Risk

Less reliance on global logistics and geopolitical disruptions


Expand Our ESG Horizons through Global Supply Chain Collaboration



Supplier Evaluation

100%

of new suppliers agreed to the Social Responsibility & Ethical Commitment Letter.



Environmental Assessment

53 locations

assessed for biodiversity and environmental impact to mitigate ecological risks (4 operating sites & 30 key suppliers).



Carbon Inventory

Scope 3 GHG Inventory

Launched to inventory upstream and downstream indirect emissions to manage supply chain carbon footprint.

Regulatory

Adam Lai

Regulatory Expectation for Pharma Industry



- Dossier Submission
- GMP
- Labeling
- Post-approval

Drug Substance

Typical Requested Documents

- Completed DMF open part
- Support of DMF close part submit to authority
- Latest regulation requirement, e.g. nitrosamine, genotoxic, elemental impurities
- Manufacturing license, GMP certificate
- GMP status for starting materials, intermediates
- Summary of changes (and close part) for better categorization evaluation

Key Collaborations

- Development progress, DMF availability
- Planned/unplanned changes
- Regulatory strategy for information reduction during initial submission, e.g. redefining key starting materials and its GMP availability
- Compendial update (inclusion of USP/EP/JP)

Key trending topics:

- Definition of starting materials (ICH Q11)
- Confirmatory testing of nitrosamines & method validation
- Reference standard specification & analytical procedures

lotus PHARMACEUTICAL

Excipient

Typical Requested Documents

- COA, compliance to USP/EP/JP
- Regulatory statement: nitrosamine, elemental impurity, residual solvents, TSE/BSE
- Pre-mix composition

Key Collaborations

- New mixture with safety data or other approval use
- Planned/ unplanned changes

Key trending topics:

- Colorant: FDA removal of FD&C Red No. 3 and probation list for synthetic dyes
- Co-process: EMA request to disclose composition, manufacturing flow charts and functionality tests

Packaging Material

Typical Requested Documents

- COA, technical data sheet, drawing, IR spectrum
- Regulatory statement: suitable for food and pharma packing (US/EU)
- Proof of performance: child resistant, USP 661/670/671, MVTR

Key Collaborations

- Planned/ unplanned changes

Key trending topics:

- Extractable & leachable/USP 665 statements: request compliance to food grade
- Updates in USP 661.1/661.2

Example - Variation Approval Time

Materials	Variation plan	Critical market	Variation level	Approval timeline
Drug substances	Drug substance batch size scale up (Within 10-fold)	EU	Type IA	Annual report
		VN	Minor change	18-24M
Excipients	Change in capsule (or other premixed materials) composition	EU	Type IA	1M
		BR	Major	6-12M
Packaging materials	Change in shape or dimension (thickness) of immediate packaging	EU	Type IA	1M
		HK	Minor change	12-18M

Supplier Chain Management

Amy Lin

Go to Lotus Webesite
Click "Sustanability" -> Supply Chain Management

https://www.lotuspharm.com/en

Open PO expediting Process

Betty Chiu

Open PO expediting processes

Example of Expediting PO message as below:

Reminder – Upcoming PO Deliveries & Required Pre-Shipment Documents / 提醒 – 即將交付採購單及所需裝運文件

Daniela Gavrilova(PS DM)
[redacted]
Cc Elise Chen(PS PK)陳怡紫

This message was sent with High importance.
If there are problems with how this message is displayed, click here to view it in a web browser.

Dear [redacted]
親愛的 [redacted]

This is a courteous reminder regarding your open purchase orders scheduled for delivery within the next three (3) months (including overdue).
謹此提醒，以下為您在未來三個月內(含過期未交)預計交付的採購訂單。

To ensure smooth processing and timely receipt of goods, please submit the following **pre-shipment documents** at least **one (1) week prior to dispatch:**
為確保順利處理並準時收貨，請於**出貨前至少一週**提供以下**裝運文件：**

- **Commercial Invoice / 商業發票**
- **Packing List / 包裝單**
- **Certificate of Analysis (COA) / Certificate of Conformance (COC) / 分析證書或符合性證書**
- **Air Waybill (AWB) / Bill of Lading (B/L) / 空運提單或海運提單** (*Applicable for overseas suppliers / 適用於海外供應商*)

Timely submission of these documents is essential for pre-shipment review and release.
請準時提供上述文件，以便進行裝運前審核與放行。

Summary of Open Purchase Orders Due Within 3 Months (including overdue)/ 未來三個月內預計交付的採購單摘要 (含過期未交)


Be Responsive

Fast confirmation prevents delivery slippage and release delays.

1. **Review details immediately.**
   Check PO number, item, quantity and delivery date.
2. **Confirm quantities and dates.**
   Align the request with production and shipping schedules.
3. **Escalate any deviations.**
   Contact the buyer right away if plans have changed.

Submit documents ≥ 1 week before dispatch

Your Action Plan



Delivering right. Delivering on time.

Code of Conduct

Keerthi

Commitment Sought
我們承諾

Corporate Social Responsibility
企業社會責任
기업의 사회적 책임

The Company is committed to upholding human rights, ensuring fair wages, and respecting freedom of association and collective bargaining. This commitment reflects a dedication to ethical business conduct and transparency in information disclosure.

公司致力於維護人權，
確保公平的工資，尊重結社自由和集體談判。這一承諾反映了對道德商業行為和資訊披露透明度的專注。

회사는 인권을 보호하고 공정한 임금을 보장하며 노조 결성의 및 단체 교섭의 자유를 존중하기 위해 최선을 다합니다. 이러한 약속은 윤리적 비즈니스 행동과 정보 공개의 투명성에 대한 헌신을 반영합니다.

Environmental Sustainability
永續環境發展
환경적 지속성

The Company pledges to minimize environmental impact, conserve resources, and track energy and resource consumption, aligning with the growing emphasis on sustainable practices in the business world.

公司承諾減少對環境的影響，節約資源，並跟蹤能源和資源消耗，這與商業世界對實踐永續的日益重視一致。

회사는 사업 영역 내에서 지속 가능한 관행에 대한 중요성이 점차 커지고 있는 추세를 이해하고 환경에 미치는 영향을 최소화하고 자원을 보존하며 에너지 및 자원 소비를 추적할 것을 약속합니다.

Basic Human Rights
基本人權
기본 인권

Demonstrating a comprehensive approach to ensuring the well-being of its workforce which also includes The Company's commitment extends to protect female employees during pregnancy and childbirth,

公司的承諾延伸到在懷孕和分娩期間保護女性員工，展示了確保員工福祉的綜合方法。

회사는 임신 중이거나 및 출산 이후의 여성 직원을 보호하기 위해 노력을 기울이며, 직원의 복지를 보장하기 위한 포괄적인 접근 방식을 보장합니다.

lotus PHARMACEUTICAL

Corporate Social responsibility
企業社會責任
기업의 사회적 책임

Labour & Human Rights
勞工與人權
노동과 인권

- Voluntary Employment
  自願就業 자발적 고용
- Prevention of Child Labour
  禁止童工 아동 노동의 예방
- Respect of Freedom of Association
  尊重結社自由 결사의 자유 존중

Health & safety
健康與安全
건강과 안전

- Occupational Safety
  職業安全 직업 안전
- Health and safety information
  健康與安全資訊 건강 및 안전 정보
- Emergency response
  緊急應變措施 긴급 대응 조치

Environmental Sustainability & Impact
永續環境發展 환경 지속 가능성과 영향

Minimising Environmental Impact

最小化對環境的影響
환경에 미치는 영향의 최소화

The Company's commitment to minimizing environmental impact and obtaining environmental permits reflects a proactive stance on environmental sustainability.

公司致力於將環境影響降至最低並獲得環境許可，這反映了公司對永續環境的積極態度。

회사는 환경에 대한 영향을 최소화하고 환경 관련 허가를 획득하기 위해 노력하며,
환경적 지속 가능성에 대한 적극적인 입장을 반영합니다.

Resource conservation

節約資源
자원 절약

By conserving resources and tracking energy and resource consumption, the Company aligns with the growing emphasis on sustainable resource management.

通過節約資源和跟蹤能源和資源消耗，公司與對永續資源管理的日益重視保持一致。

회사는 자원을 보존하고 에너지와 자원 소비를 추적 관리함으로써 지속 가능한 자원 관리에 대한 강조가 점차 높아지는 추세에 발맞추어 운영합니다.

Pollution Prevention

污染防治
오염 방지

The Company's focus on preventing pollution and controlling wastewater and air emissions demonstrates a commitment to environmental stewardship.

公司專注於污染防治和控制廢水和空氣排放，這表明對環境管理的承諾。

회사는 오염 방지, 폐수 및 대기 배출 물질 관리에 중점을 두며,
이는 환경 관리에 대한 헌신을 보여줍니다.

Ethical Standards and Transparency
道德標準和透明度 정보 공개의 투명성

Transparency in Information Disclosure (資訊披露的透明度) (정보 공개의 투명성)

The Company's commitment to transparency in information disclosure and cooperation with audit organizations which reflects a dedication to ethical business conduct and accountability.

公司致力於資訊披露的透明度以及與審計機構的合作，這反映了對道德商業行為和問責制的專注。

회사는 정보 공개에 있어 투명성을 추구하고 감사 기관과 협력하며 윤리적 사업 행위와 책임에 대한 헌신을 반영합니다.

Intellectual Property Protection (知識產權保護) (지적재산권 보호)

Respecting intellectual property and information confidentiality showcases the Company's commitment to upholding ethical standards and protecting proprietary information.

尊重智慧財產權和資訊保密性表明公司對維護道德標準和保護專有信息的承諾。

지적 재산 및 정보 기밀 유지를 통해 윤리적 기준을 준수하고 독점 정보를 보호하기 위한 회사의 노력을 보여줍니다.

Avoidance of Conflicts of Interest (避免利益衝突) (이해충돌 방지)

The Company's commitment to avoiding conflicts of interest demonstrates a dedication to ethical business practices and integrity.

公司致力於避免利益衝突，體現了對道德商業實踐和誠信的專注。

회사는 이해 상충을 피하기 위해 노력하며 윤리적 비즈니스 관행과 무결성에 대한 헌신을 보여줍니다.

Supplier Evaluation

Amit Razdan

供應商評鑑標準 **Supplier evaluation & Rating**

Evaluation Aspect 評比面向	Evaluation Indicator 評比指標	Score proportion 評分占比	Evaluation unit 評鑑單位
Availability 供貨	• On-time delivery performance • Delivery reliability & consistency • Lead time management	20%	Delivery performance records, PO data, system reports 交期績效記錄、訂單資料、系統報告
Quality 品質	• Conformance to specifications • Defect rate / PPM • Quality system & certifications • Corrective & preventive actions (CAPA)	25%	Quality reports, audit results, inspection records 品質報告、稽核結果、檢驗記錄
Service 服務	• Responsiveness & communication • Supportiveness & issue resolution • Technical support capability • Overall service satisfaction	20%	Service records, feedback, survey results 服務記錄、回饋、調查結果
Cost 成本	• Pricing competitiveness • Cost efficiency / TCO • Cost reduction initiatives • Price stability	15%	Price comparison, cost data, savings reports 價格比較、成本資料、節省報告
Innovation 創新	• New product / solution proposals • Process improvement initiatives • Technology & value-added innovation • Continuous improvement mindset	10%	Innovation proposals, project outcomes, improvement results 創新提案、專案成果、改善結果
ESG 環境、社會與公司治理	• Environmental management • Social responsibility & labor practices • Governance & business ethics • Compliance & risk management	10%	ESG reports, certifications, audit results, compliance records ESG 報告、認證、稽核結果、合規記錄
	Total Score Proportion 總分占比： 100%		

Best Service Supplier

Nominations- 2025

- Changzhou Pharmaceutical Factory
- MSN Laboratories
- Yeasing
- Alivus Life Science
- ACG Pharmapack
- U-Liang
- Matrix Pharmacorp Private Limited
- Crestec
- Waters
- Beijing Geyuantianrun
- SZ Printing
- Syntegon
- Chemexpress

Award

Goes to

Company Name : Beijing Geyuantianrun

Reasons

- No rejections
- Product Quality improvement
- Price improvement initiatives



IN Supplier Conference_ June 3rd 2026



TW Supplier Conference_ June 24th 2026



Thanks!